Vinblastine and erythromycin : an unrecognized serious drug interaction

Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1995-01, Vol.35 (3), p.188-190
Main Authors: >TOBE, S.W, SIU, L. L, JAMAL, S. A, SKORECKI, K. L, MURPHY, G. F, WARNER, E
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Biological and medical sciences
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
Chemotherapy
Constipation - chemically induced
Cyclosporine - therapeutic use
Drug Synergism
Drug Therapy, Combination
Erythromycin - adverse effects
Erythromycin - therapeutic use
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Lymphatic Metastasis
Male
Medical sciences
Middle Aged
Muscle Spasticity - chemically induced
Neutropenia - chemically induced
Pain - chemically induced
Pharmacology. Drug treatments
Vinblastine - adverse effects
Vinblastine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00686546